CN114404647A - High-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and preparation method thereof - Google Patents
High-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and preparation method thereof Download PDFInfo
- Publication number
- CN114404647A CN114404647A CN202111658888.4A CN202111658888A CN114404647A CN 114404647 A CN114404647 A CN 114404647A CN 202111658888 A CN202111658888 A CN 202111658888A CN 114404647 A CN114404647 A CN 114404647A
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- beta
- polysiloxane
- gqds
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 33
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229910052710 silicon Inorganic materials 0.000 title claims abstract description 22
- 239000010703 silicon Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- -1 polysiloxane Polymers 0.000 claims abstract description 57
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 48
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 44
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 44
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 44
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 44
- 229960004853 betadex Drugs 0.000 claims abstract description 44
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 23
- 239000001257 hydrogen Substances 0.000 claims abstract description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 19
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000908 ammonium hydroxide Substances 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001556 precipitation Methods 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229910021389 graphene Inorganic materials 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 239000002096 quantum dot Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 3
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 229940086555 cyclomethicone Drugs 0.000 claims description 2
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 claims description 2
- 229920000570 polyether Polymers 0.000 claims description 2
- 229920001843 polymethylhydrosiloxane Polymers 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 1
- 229960004543 anhydrous citric acid Drugs 0.000 abstract description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 229960004106 citric acid Drugs 0.000 abstract description 3
- 230000003139 buffering effect Effects 0.000 abstract description 2
- 229910052799 carbon Inorganic materials 0.000 abstract description 2
- 238000001027 hydrothermal synthesis Methods 0.000 abstract description 2
- 239000003094 microcapsule Substances 0.000 abstract description 2
- 230000002459 sustained effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000416 hydrocolloid Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 238000007719 peel strength test Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/108—Elemental carbon, e.g. charcoal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and a preparation method thereof, wherein the composition comprises the following raw materials: citric acid, ammonium hydroxide, ethanol, polysiloxane with the viscosity value of 1000-3000, hydrogen-containing polysiloxane with the viscosity value of 700-1500 and beta-cyclodextrin. The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition takes anhydrous citric acid, ammonium hydroxide, ethanol, polysiloxane-containing polysiloxane and beta-cyclodextrin as raw materials, wherein the anhydrous citric acid is taken as a carbon source to prepare graphene quantum dots by a hydrothermal method; embedding the prepared graphene quantum dots by using beta-cyclodextrin as a carrier by adopting a precipitation method to prepare N-GQDs/beta-cyclodextrin microcapsules so as to achieve a sustained and slow release antibacterial effect; polysiloxane and polysiloxane containing hydrogen can be used as main frame of the composition, and can be mixed and cured into gel state, and has the advantages of water resistance, good flexibility, buffering property, skin adhesion, no peeling pain and repeated adhesion.
Description
Technical Field
The invention belongs to the field of new medical materials, relates to an ostomy care composition, and particularly relates to a high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and a preparation method thereof.
Background
The stoma refers to that a diseased intestinal section needs to be cut off through an operation, only one section of intestinal tube is pulled out, turned over and sewn on the abdominal wall for excreting excrement. In the current medical care, a medical hydrocolloid ostomy base plate is mainly used as a common care product. At present, the main material of the stoma base plate is medical hydrocolloid consisting of rubber and water-absorbing polymers. Such medical hydrocolloids have the primary function of absorbing peristomal excreta to reduce leakage. However, the prior medical hydrocolloid has the problems of poor wet viscosity, easy adhesive residue, pressure injury caused by overlarge peeling force, fecal dermatitis caused by long-term contact of peripheral skin with excrement, disposable sticking and the like. In addition, due to the development trend of the medical industry, the demand of the ostomy base plate with sustainable antibacterial property is gradually increased, so that the ostomy market urgently needs an ostomy care substance with good skin compliance, softness, comfort and good biocompatibility to replace the medical hydrocolloid.
Disclosure of Invention
The invention aims to solve the defects that the ostomy base plate prepared from the existing medical hydrocolloid has poor wet viscosity, is easy to remain glue, has overlarge stripping force and can be pasted only once, and provides a high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition with good skin compliance, softness, comfort and good biocompatibility.
The invention also provides a preparation method of the high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition.
In order to achieve the purpose, the invention adopts the following technical scheme:
a high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight: 1-10 parts of citric acid, 10-20 parts of ammonium hydroxide, 30-40 parts of ethanol, 40-60 parts of polysiloxane with the viscosity value of 1000-3000, 30-40 parts of hydrogenpolysiloxane with the viscosity value of 700-1500 and 20-50 parts of beta-cyclodextrin.
In the invention, the composition overcomes the problem of poor viscosity of the traditional silica gel, absorbs the advantage of the silica gel on scar repair, and introduces the graphene oxide quantum dot powder capsule which takes beta-cyclodextrin as a shell and is wrapped inside in the composition synthesis process to achieve the slow-release antibacterial effect. The composition of the invention can achieve the effects of good skin compliance, corrosion resistance, softness and comfort, skin repair and slow-release antibacterial effect.
The invention selects two siloxane compounds with different viscosity ranges to carry out micro-regulation on the viscosity of the prepared gel so as to achieve the effects of better skin compliance and good viscosity.
As a preferable scheme of the invention, the polysiloxane comprises one or a mixture of polydimethylsiloxane, cyclomethicone, aminosiloxane, polymethylphenylsiloxane, vinyl polydimethylsiloxane cross-linked polymer, cyclopentadimethylsiloxane and polyether polysiloxane copolymer.
In a preferred embodiment of the present invention, the hydrogen-containing polysiloxane comprises methylhydrogen siloxane.
The preparation method of the high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following steps:
1) preparing graphene quantum dot powder: reacting citric acid with ammonium hydroxide under acidic condition, centrifuging after reaction, collecting supernatant, and freeze drying to obtain N-GQDs powder;
2) preparing N-GQDs/beta-cyclodextrin capsules: preparing N-GQDs/beta-cyclodextrin capsules by using the N-GQDs powder obtained in the step 1) and beta-cyclodextrin as raw materials by a precipitation method;
3) preparation of N-GQDs/beta-cyclodextrin capsules-hydrogen-containing polysiloxane mixture: adding the N-GQDs/beta-cyclodextrin capsules obtained in the step 2) into hydrogen-containing polysiloxane and stirring to obtain a mixture of the N-GQDs/beta-cyclodextrin capsules and the hydrogen-containing polysiloxane;
4) mixing: mixing the N-GQDs/beta-cyclodextrin capsule-hydrogen-containing polysiloxane mixture obtained in the step 3) with polysiloxane to obtain a mixture;
5) and (3) curing: injecting the mixture obtained in the step 4) into a mould for curing to obtain the high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition.
As a preferable scheme of the invention, in the step 1), the pH value of the acidic condition is 2-5, the reaction condition is that the temperature is 100-200 ℃, and the reaction time is 12-36 h.
As a preferable scheme of the invention, in the step 2), the mass ratio of the beta-cyclodextrin to the N-GQDs powder is 2-10: 1.
As a preferable scheme of the invention, in the step 2), the reaction conditions for preparing the N-GQDs/beta-cyclodextrin capsules are that the temperature is 25-65 ℃, the stirring time is 2-10 h, and the stirring speed is 300-1500 r/min.
As a preferable scheme of the invention, in the step 3), the stirring time is 1-10h, and the stirring speed is 50-100 r/min.
As a preferable scheme of the invention, in the step 4), the mixing temperature is 10-30 ℃, and the mixing time is 1-10 h.
As a preferable scheme of the invention, in the step 5), the curing temperature is 100-130 ℃, and the curing time is 10-30 min.
Compared with the prior art, the invention has the following beneficial effects:
the high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition takes anhydrous citric acid, ammonium hydroxide, ethanol, polysiloxane-containing polysiloxane and beta-cyclodextrin as raw materials, wherein the anhydrous citric acid is taken as a carbon source to prepare graphene quantum dots by a hydrothermal method; embedding the prepared graphene quantum dots by using beta-cyclodextrin as a carrier by adopting a precipitation method to prepare N-GQDs/beta-cyclodextrin microcapsules so as to achieve a sustained and slow release antibacterial effect; polysiloxane and polysiloxane containing hydrogen can be used as main frame of the composition, and can be mixed and cured into gel state, and has the advantages of water resistance, good flexibility, buffering property, skin adhesion, no peeling pain and repeated adhesion.
Detailed Description
The technical solutions in the embodiments will be described clearly and completely with reference to the embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight: 5 parts of anhydrous citric acid, 10 parts of ammonium hydroxide, 30 parts of ethanol, 40 parts of polysiloxane, 30 parts of hydrogen-containing polysiloxane and 50 parts of beta-cyclodextrin;
example 2
The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight: 6 parts of anhydrous citric acid, 12 parts of ammonium hydroxide, 32 parts of ethanol, 45 parts of polysiloxane, 32 parts of hydrogen-containing polysiloxane and 48 parts of beta-cyclodextrin;
example 3
The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight: 7 parts of anhydrous citric acid, 14 parts of ammonium hydroxide, 34 parts of ethanol, 50 parts of polysiloxane, 34 parts of hydrogen-containing polysiloxane and 42 parts of beta-cyclodextrin;
example 4
The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight: 8 parts of anhydrous citric acid, 16 parts of ammonium hydroxide, 36 parts of ethanol, 55 parts of polysiloxane, 36 parts of hydrogen-containing polysiloxane and 32 parts of beta-cyclodextrin;
example 5
The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight: 9 parts of anhydrous citric acid, 18 parts of ammonium hydroxide, 38 parts of ethanol, 60 parts of polysiloxane, 38 parts of hydrogen-containing polysiloxane and 18 parts of beta-cyclodextrin;
example 6
The high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition comprises the following raw materials in parts by weight:
40 parts of polysiloxane and 40 parts of hydrogen-containing polysiloxane;
the preparation method comprises the following steps:
step one, preparing graphene quantum dot powder: dissolving anhydrous citric acid in deionized water, adjusting the pH value of the obtained solution to about 2.0-5.0 by using ammonium hydroxide, then placing the solution into a stainless steel autoclave lined with Teflon, and heating the solution at the temperature of 100-200 ℃ for 12-36 hours; cooling to room temperature, centrifuging the reaction mixture, collecting the centrifuged supernatant as original N-GQDs solution, and freeze-drying to obtain N-GQDs powder;
step two, preparing the N-GQDs/beta-cyclodextrin capsule: the N-GQDs/beta-cyclodextrin capsule is prepared by a precipitation method. Magnetically stirring at 30-50 deg.C, dissolving a certain amount of beta-cyclodextrin in a proper amount of ethanol/water (volume ratio of 1: 2) mixture to obtain saturated cyclodextrin ethanol-water mixed solution; N-GQDs powder is prepared by mixing N-GQDs powder according to a mass ratio of 1: 20, dissolving in absolute ethyl alcohol by ultrasonic wave, then slowly adding a beta-cyclodextrin solution, and setting the wall-core ratio as 2: 1,4: 1,6: 1, 8:1 and 10:1, keeping heating, respectively setting the temperature to be 25, 35, 45, 55 and 65 ℃, respectively, stirring for 2, 3, 6, 8 and 10 hours, respectively, and respectively setting the stirring speed to be 300, 600, 900, 1200 and 1500r/min for embedding; carrying out vacuum filtration by a vacuum pump after embedding, and carrying out freeze drying on the obtained solid to obtain an N-GQDs/beta-cyclodextrin capsule;
step three, preparing a mixture of N-GQDs/beta-cyclodextrin capsules and low-viscosity hydrogen-containing polysiloxane: respectively adding the N-GQDs/beta-cyclodextrin capsules prepared in the step two into the low-viscosity (1000-3000) hydrogenous polysiloxane compound for stirring for 1-10h at the rotating speed of 50-100r/min to obtain an N-GQDs/beta-cyclodextrin capsule-low-viscosity hydrogenous polysiloxane mixture;
mixing the N-GQDs/beta-cyclodextrin capsule-low-viscosity hydrogen-containing polysiloxane mixture and polysiloxane, and mixing for 1-10h at a fixed temperature of 10-30 ℃;
and step five, injecting the mixture obtained in the step four into a mold, and curing at a fixed temperature of 100 ℃ and 130 ℃ for 10-30min to obtain the high-viscosity slow-release antibacterial water-resistant silica gel.
And sixthly, demolding the silica gel, covering a single-layer acrylic acid pressure-sensitive adhesive polyurethane foam layer with the thickness of 0.2-0.4mm on one surface of the silica gel to be used as a back lining layer, and covering release paper on the other surface of the silica gel to be used as a release layer to obtain the high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition 1, 2, 3, 4, 5 and 6.
And (3) detecting the material performance:
the compositions 1, 2, 3, 4, 5, 6 finally obtained in the above examples 1 to 6 were subjected to the following tests, respectively:
experiment one: water-blocking property
The above composition was tested for water repellency as follows (reference: YY/T0471.3-2004 contact wound dressing test method part 3: Water repellency):
the cell was filled with purified water at (21 st 2) c and the sample was placed on the lower ring in a horizontal sliding manner to avoid air between the surface of the water and the lower surface of the sample. The sample was covered with a dry filter paper larger than the test area, placed on the upper ring and clamped with a screw device. Fill the tube with human water to the desired level above the surface of the sample. The hydrostatic pressure (300 km 10) s was maintained. The filter paper was checked for water penetration through the sample and the results recorded.
Experiment two: elongation at break
The composition is taken for breaking elongation test, and the test method is as follows:
the universal tester is started to test at a specified speed. The sample to be tested is placed in the two clamps of the tester with appropriate tightness to prevent loading. After the sample breaks, reading the required load and the corresponding elongation value between the marked lines and the maximum load number of the break, and calculating according to the following formula:
E＝(L-L1)/L1*100％；
wherein E- -elongation at break, unit is%.
L- -distance between lines at break or yield time of the specimen in mm.
L1 — original gage mark distance of sample in mm.
Experiment three: peel Strength test
The composition is taken to carry out a peel strength test, and the test method is as follows (reference: GB/T2792-2014 adhesive tape peel strength test method):
a2.5 cm wide strip of the composition was adhered to a stainless steel plate which was fixed to one of the clamps of a tensile tester, and the other clamp of the tester was clamped to the free end of the strip to be tested at an angle of 180 DEG to the stainless steel plate, and the strip to be tested was pulled apart at a prescribed rate. The peel force is measured by the force required to continuously peel the strip from the stainless steel plate and converted to peel strength.
Experiment four: continuous antibacterial effect test (refer to WS/T650-2019 antibacterial and antibacterial effect evaluation methods):
preparing a long-acting antibacterial sample tablet:
selecting bionic skin, cutting into 50mm × 50mm, and preparing antibacterial sample. Cutting the composition 1-5, sticking the cut composition on the surface of a sample wafer with the same size as the bionic skin, and drying at room temperature for later use as an experimental group; applying composition 6 to an untreated sample (autoclaved) as a control; both sets of coupons were stored in the laboratory at room temperature.
And (3) long-acting antibacterial test:
after the two groups of samples are respectively stored for 1d, 3d, 5d and 7d at room temperature, the experimental group and the control group are taken out for testing. Dyeing the 24h fresh cultured strain suspension on a carrier, putting the carrier of the experimental group infected strain into a neutralizer after the carrier acts for 30min, and diluting and inoculating after uniformly mixing; and simultaneously, carrying out parallel test by using a control group sample plate to infect bacteria, putting a control group infectious bacteria carrier into the diluent at the same time, uniformly mixing, diluting and inoculating. The final results are observed by culturing the bacterial propagules for 48 hours at 36 +/-1 ℃ and culturing the aspergillus niger for 72 hours at 30 +/-1 ℃, and the recovery bacterial amount after the control vector is infected is 1.0 multiplied by 104 CFU/tablet to 9.0 multiplied by 104 CFU/tablet. Taking the test same batch of diluent, neutralizer and culture medium as negative control. The test was repeated 3 times and the sterilization rate was calculated.
The formula is as follows:
x-sterilization rate,%;
a-recovery of bacteria for control samples in CFU/chip (or specimen);
b-recovery of bacteria from test specimens in CFU/chip (or specimen).
The results of the composition performance tests are shown in Table 1.
TABLE 1 composition Performance test results
The results of the composition on-going antibacterial tests are shown in table 2.
Table 2 composition continuous antimicrobial test results
Through analysis of the test results, the hardness of the obtained composition is increased and the viscosity is reduced along with the increase of the hydrogen-containing polysiloxane, the composition is softer along with the reduction of the hydrogen-containing polysiloxane, the elongation at break is increased, the skin compliance is better, meanwhile, according to the result of the continuous antibacterial test, the continuous antibacterial capability is increased and then reduced along with the continuous increase of the wall-core ratio of the graphene quantum dots to the beta-cyclodextrin, the composition with the continuous antibacterial capability for 7 days is the compositions 2, 3, 4 and 5, and the use requirement of clinical stoma care products is met. Meanwhile, the antibacterial ability of the composition reaches a peak value after 3d, and the reason that the graphene quantum dots are dissolved out after the beta cyclodextrin is combined with the hydrophilic groups on the surface of the bionic skin is presumed. In combination, composition 3 exhibited enhanced antimicrobial capability and was optimized for mechanical testing. The preferred embodiment is therefore combination 3.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that the foregoing and other changes, omissions and deviations in the form and detail thereof may be made without departing from the scope of this invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.
Claims (10)
1. A high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition is characterized by comprising the following raw materials in parts by weight: 1-10 parts of citric acid, 10-20 parts of ammonium hydroxide, 30-40 parts of ethanol, 40-60 parts of polysiloxane with the viscosity value of 1000-3000, 30-40 parts of hydrogenpolysiloxane with the viscosity value of 700-1500 and 20-50 parts of beta-cyclodextrin.
2. The silicon-containing ostomy care composition with high viscosity, slow release, antibacterial and water blocking property as claimed in claim 1, wherein the polysiloxane comprises one or more of polydimethylsiloxane, cyclomethicone, aminosiloxane, polymethylphenylsiloxane, vinyl polydimethylsiloxane crosspolymer, cyclopentadimethylsiloxane, polyether polysiloxane copolymer.
3. The high viscosity, sustained release, antibacterial, water resistant silicone-containing ostomy care composition according to claim 1 wherein the hydrogen-containing polysiloxane comprises methylhydrogen siloxane.
4. A method for preparing a high viscosity, sustained release, antibacterial, water-blocking silicon-containing ostomy care composition according to any one of claims 1-3, comprising the steps of:
1) preparing graphene quantum dot powder: reacting citric acid with ammonium hydroxide under acidic condition, centrifuging after reaction, collecting supernatant, and freeze drying to obtain N-GQDs powder;
2) preparing N-GQDs/beta-cyclodextrin capsules: preparing N-GQDs/beta-cyclodextrin capsules by using the N-GQDs powder obtained in the step 1) and beta-cyclodextrin as raw materials by a precipitation method;
3) preparation of N-GQDs/beta-cyclodextrin capsules-hydrogen-containing polysiloxane mixture: adding the N-GQDs/beta-cyclodextrin capsules obtained in the step 2) into hydrogen-containing polysiloxane and stirring to obtain a mixture of the N-GQDs/beta-cyclodextrin capsules and the hydrogen-containing polysiloxane;
4) mixing: mixing the N-GQDs/beta-cyclodextrin capsule-hydrogen-containing polysiloxane mixture obtained in the step 3) with polysiloxane to obtain a mixture;
5) and (3) curing: injecting the mixture obtained in the step 4) into a mould for curing to obtain the high-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition.
5. The preparation method according to claim 4, wherein in the step 1), the pH value of the acidic condition is 2-5, the reaction condition is that the temperature is 100-200 ℃, and the reaction time is 12-36 h.
6. The method according to claim 4, wherein the mass ratio of the β -cyclodextrin to the N-GQDs powder in step 2) is 2-10: 1.
7. The preparation method according to claim 4, wherein the N-GQDs/beta-cyclodextrin capsule in the step 2) is prepared under the reaction conditions of 25-65 ℃ of temperature, 2-10 h of stirring time and 300-1500 r/min of stirring speed.
8. The preparation method according to claim 4, wherein in the step 3), the stirring time is 1h to 10h, and the stirring speed is 50r/min to 100 r/min.
9. The method according to claim 4, wherein the mixing temperature in step 4) is 10 ℃ to 30 ℃ and the mixing time is 1h to 10 h.
10. The method according to claim 4, wherein in the step 5), the curing temperature is 100 ℃ to 130 ℃ and the curing time is 10min to 30 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111658888.4A CN114404647A (en) | 2021-12-30 | 2021-12-30 | High-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111658888.4A CN114404647A (en) | 2021-12-30 | 2021-12-30 | High-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114404647A true CN114404647A (en) | 2022-04-29 |
Family
ID=81270040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111658888.4A Pending CN114404647A (en) | 2021-12-30 | 2021-12-30 | High-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114404647A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1234743A (en) * | 1996-11-25 | 1999-11-10 | 金伯利-克拉克环球有限公司 | Adhesive composition comprising polysiloxane |
| CN105267976A (en) * | 2015-10-14 | 2016-01-27 | 重庆华邦制药有限公司 | Graphene-oxide cyclodextrin compound and preparation method thereof |
| CN108064844A (en) * | 2017-12-18 | 2018-05-25 | 河北工业大学 | A kind of cyclodextrin modified graphene-houghite pesticide slow-releasing agent and preparation method thereof |
| CN110931271A (en) * | 2019-12-24 | 2020-03-27 | 桂林电子科技大学 | Preparation and application of hydrophobic Schiff base cobalt @ β cyclodextrin-graphene porous carbon composite material |
| CN112251064A (en) * | 2020-10-28 | 2021-01-22 | 桂林理工大学 | Preparation method of modified beta-cyclodextrin-GO composite material |
| CN113337283A (en) * | 2021-06-07 | 2021-09-03 | 宁德师范学院 | Synthetic method and application of nitrogen-doped graphene quantum dots |
-
2021
- 2021-12-30 CN CN202111658888.4A patent/CN114404647A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1234743A (en) * | 1996-11-25 | 1999-11-10 | 金伯利-克拉克环球有限公司 | Adhesive composition comprising polysiloxane |
| CN105267976A (en) * | 2015-10-14 | 2016-01-27 | 重庆华邦制药有限公司 | Graphene-oxide cyclodextrin compound and preparation method thereof |
| CN108064844A (en) * | 2017-12-18 | 2018-05-25 | 河北工业大学 | A kind of cyclodextrin modified graphene-houghite pesticide slow-releasing agent and preparation method thereof |
| CN110931271A (en) * | 2019-12-24 | 2020-03-27 | 桂林电子科技大学 | Preparation and application of hydrophobic Schiff base cobalt @ β cyclodextrin-graphene porous carbon composite material |
| CN112251064A (en) * | 2020-10-28 | 2021-01-22 | 桂林理工大学 | Preparation method of modified beta-cyclodextrin-GO composite material |
| CN113337283A (en) * | 2021-06-07 | 2021-09-03 | 宁德师范学院 | Synthetic method and application of nitrogen-doped graphene quantum dots |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102142446B1 (en) | Polymer composites of silicone ionomers | |
| CA2576745C (en) | Ostomy appliance with recovery resistant moldable adhesive | |
| EP2350221B1 (en) | Gentle to skin adhesive | |
| JP5690398B2 (en) | Antibacterial gel | |
| KR20140116902A (en) | Curable compositions of ionic silicones | |
| JP7047316B2 (en) | Silicone rubber-based curable compositions, silicone rubbers, moldings and medical tubes | |
| US10370571B2 (en) | Silicone gel adhesive with hydrophillic and antimicrobial properties | |
| Ohura et al. | Evaluating dressing materials for the prevention of shear force in the treatment of pressure ulcers | |
| CN113499484A (en) | Surface hydrophilic layer modification method for implantable medical device and application | |
| JP2018510675A (en) | Adhesive for wet tissue and peristomal device made using the same | |
| CN114209891A (en) | Wet-state-adhered super-lubricating hydrogel coating and preparation method thereof | |
| US20220411678A1 (en) | Reversible adhesives | |
| CN114404647A (en) | High-viscosity slow-release antibacterial water-resistant silicon-containing ostomy care composition and preparation method thereof | |
| Singh et al. | A tunable soft silicone bioadhesive for secure anchoring of diverse medical devices to wet biological tissue | |
| CN117379605A (en) | Medical silica gel surface hydrophilic modified coating and preparation method and application thereof | |
| CN109602729B (en) | Preparation method of hydrogel film with high skin adhesion and capable of promoting wound healing | |
| CN109337492B (en) | Hydrophilic super-smooth coating and activation-free coating catheter | |
| CN115160482B (en) | Skin protection film material and preparation method and application thereof | |
| CN104474592B (en) | Medical organosilicone material for pancreas and intestine anastomosis instrument and preparation method thereof | |
| JP2012211246A (en) | Curable silicone rubber composition and measuring method for curable silicone rubber composition | |
| CN113289054A (en) | Wound dressing capable of absorbing heat rapidly and preparation method and application thereof | |
| WO2012003028A1 (en) | Silicone gel adhesives with organic polyhydroxy compounds | |
| CN112538271A (en) | Hydrophilic silicone rubber capable of being used as medical catheter and preparation method and application thereof | |
| WO2021124200A1 (en) | Adhesive primers and articles including the same | |
| CN1039590C (en) | Medical stick-resistant silastic membrane and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220429 |